Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10E8.4/iMab in HIV-1-infected and Uninfected Individuals
NCT03875209Phase 1Completed
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 10E8.4/iMab in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoints: Safety of the highest single intravenous dose of 10E8.4/iMab in HIV uninfected individuals at 24 weeks, Safety of the highest single intravenous dose of 10E8.4/iMab in HIV infected individuals at 24 weeks and 2 more. Started Apr 2019; status: completed.
02
Drugs
10E8.4/iMab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03875209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875209.